Log In
Print this Print this


Also known as: ADH300004 (formerly 776C85)

  Manage Alerts
Collapse Summary General Information
Company Fennec Pharmaceuticals Inc.
DescriptionDihydropyrimidine dehydrogenase inhibitor
Molecular Target Dihydropyrimidine dehydrogenase
Mechanism of ActionDihydropryimidine dehydrogenase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat anthracycline-resistant breast cancer; Treat breast cancer; Treat metastatic breast cancer; Treat taxane-resistant breast cancer
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today